Roman Yelensky

Roman Yelensky

Company: Gritstone Oncology

Job title: Chief Technology Officer

Bio:

Bio: Dr. Roman Yelensky is Gritstone Oncology’s first employee and serves as chief technology officer, with responsibility for the EDGETM tumor antigen identification platform. Previously, Dr. Yelensky was vice president at Foundation Medicine, which he joined at its inception. At Foundation Medicine, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Dr. Yelensky established Foundation Medicine’s FDA-regulated products program, leading to FDA approval of the first NGS-based companion diagnostic. He holds a Ph.D. in bioinformatics and genomics from the Massachusetts Institute of Technology and has co-authored more than 75 manuscripts, including most recently on EDGE in Nature Biotechnology.

 

Seminars:

10.20 | 7.20 Live Audience Q+A 10:20 am

Read more

day: Day Two

9.40 | 6.40 Keynote Presentation: Neoantigen Targeted Cancer Immunotherapy in the Clinic 9:40 am

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.